Dr. Tina Moore highlights a new opinion piece in Diabetes Care that challenges the standard approach to GLP-1 medications like semaglutide. While the concept of microdosing is gaining popularity, Dr. Tina warns that many are misunderstanding or misapplying the term—especially when it comes to weight loss. Instead, she advocates for a more personalized, clinically-informed dosing strategy that emphasizes long-term metabolic health over quick fixes.